Evidence map›Paper›PMID 39076076›Full record

ArticleActa biochimica et biophysica Sinica2024

Structural basis for the inhibition of coronaviral main proteases by PF-00835231.

Xuelan Zhou, Xiaolu Lu, Cheng Lin, Xiaofang Zou, Wenwen Li, Xiangyi Zeng, Jie Wang, Pei Zeng, Weiwei Wang, Jin Zhang and 2 more

Abstract read
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xuelan ZhouCollege of Pharmacy, Gannan Medical University, Ganzhou 341000, China.
Xiaolu LuCollege of Pharmacy, Gannan Medical University, Ganzhou 341000, China.
Cheng LinShenzhen Crystalo Biopharmaceutical Co., Ltd., Shenzhen 518118, China.
Xiaofang ZouJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Wenwen LiJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Xiangyi ZengJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Jie WangJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Pei ZengJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Weiwei WangShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201204, China.
Jin ZhangSchool of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.
Haihai JiangSchool of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.
Jian LiCollege of Pharmacy, Gannan Medical University, Ganzhou 341000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main protease (M

Indexed as

Coronavirus 3C ProteasesCoronavirus Protease InhibitorsIndolesLeucinePyrrolidinonesCrystallography, X-RayMutationProtein DomainsStructure-Activity Relationship3C-like protease, SARS coronavirusCoronavirus 3C ProteasesCoronavirus Protease InhibitorsIndolesLeucinelufotrelvirPyrrolidinonescoronaviruscrystal structureinhibitionmain proteasePF-00835231

Identifiers

PMID39076076
PMCPMC11693862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.